ArticleOrganic & biomolecular chemistry2016
Photoswitchable anticancer activity via trans-cis isomerization of a combretastatin A-4 analog.
Article in Organic & biomolecular chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 106 citations in OpenAlex.
- Simultaneous activation and release of a microtubule inhibitor from amphiphilic polymeric nanoparticles.Nanoscale advances · 2026Article
- A Multiscale Simulation Framework for Elucidating Photochemical Structure-Activity Relationships of Photoswitchable Ligands in Complex Biomolecular Environments.Journal of chemical information and modeling · 2025Article
- Intersection of ferroptosis and nanomaterials brings benefits to breast cancer.Cell biology and toxicology · 2025Review
- Theoretical evaluation of a bulkyRSC advances · 2025Article
- Photoswitch dissociation from a G protein-coupled receptor resolved by time-resolved serial crystallography.Nature communications · 2024Article
- Effect of the Protic vs. Non-Protic Molecular Environment on theInternational journal of molecular sciences · 2024Article
- A photo-SAR study of photoswitchable azobenzene tubulin-inhibiting antimitotics identifying a general method for near-quantitative photocontrol.Chemical science · 2024Article
- Photoresponsive peptide materials: Spatiotemporal control of self-assembly and biological functions.Biophysics reviews · 2023Review
- First-in-Class Colchicine-Based Visible Light Photoswitchable Microtubule Dynamics Disrupting Agent.Cells · 2023Article
- Rapid and reversible optical switching of cell membrane area by an amphiphilic azobenzene.Nature communications · 2023Article
- Development of Combretastatin A-4 Analogues as Potential Anticancer Agents with Improved Aqueous Solubility.Molecules (Basel, Switzerland) · 2023Article
- Optochemical Control of Therapeutic Agents through Photocatalyzed Isomerization.Angewandte Chemie (International ed. in English) · 2022Article
- Photopharmacology of Antimitotic Agents.International journal of molecular sciences · 2022Review
- Article
- Photochemical OFF/ON Cytotoxicity Switching by Using a Photochromic Surfactant with Visible Light Irradiation.ACS omega · 2022Article
- Molecular Switches-Tools for Imparting Control in Drug Delivery Systems.Frontiers in chemistry · 2022Review
- Advances and opportunities in the exciting world of azobenzenes.Nature reviews. Chemistry · 2022Review
- Pyrrole Hemithioindigo Antimitotics with Near-Quantitative Bidirectional Photoswitching that Photocontrol Cellular Microtubule Dynamics with Single-Cell Precision*.Angewandte Chemie (International ed. in English) · 2021Article
- Review
- Light: A Magical Tool for Controlled Drug Delivery.Advanced functional materials · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Combretastatin A-4 (CA4) is highly potent anticancer drug that acts as an inhibitor of tubulin polymerization. The core of the CA4 structure contains a cis-stilbene, and it is known that the trans isomer is significantly less potent. We prepared an azobenzene analog of CA4 (Azo-CA4) that shows 13-35 fold enhancement in potency upon illumination. EC50 values in the light were in the mid nM range. Due to its ability to thermally revert to less toxic trans form, Azo-CA4 also has the ability to automatically turn its activity off with time. Azo-CA4 is less potent than CA-4 because it degrades in the presence of glutathione as evidenced by UV-Vis spectroscopy and ESI-MS. Nevertheless, Azo-CA4 represents a promising strategy for switchable potency for treatment of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.